Johnson & Johnson $JNJ Stake Trimmed by Obermeyer Wealth Partners

Obermeyer Wealth Partners cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 18.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,847 shares of the company’s stock after selling 2,961 shares during the quarter. Obermeyer Wealth Partners’ holdings in Johnson & Johnson were worth $2,382,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Clark Asset Management LLC grew its holdings in shares of Johnson & Johnson by 51.6% during the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after buying an additional 3,025 shares in the last quarter. Treasurer of the State of North Carolina boosted its position in Johnson & Johnson by 8.3% during the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after acquiring an additional 94,957 shares during the last quarter. Avanza Fonder AB grew its stake in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares in the last quarter. Talbot Financial LLC raised its holdings in shares of Johnson & Johnson by 4.6% in the third quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock valued at $25,667,000 after purchasing an additional 6,143 shares during the last quarter. Finally, Liberty One Investment Management LLC boosted its holdings in Johnson & Johnson by 83.9% during the third quarter. Liberty One Investment Management LLC now owns 366,813 shares of the company’s stock worth $68,040,000 after purchasing an additional 167,353 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3%

Shares of Johnson & Johnson stock opened at $218.81 on Friday. The business has a fifty day simple moving average of $205.82 and a two-hundred day simple moving average of $186.74. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The company has a market capitalization of $527.18 billion, a price-to-earnings ratio of 21.12, a P/E/G ratio of 2.26 and a beta of 0.34. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $220.11.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 14th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.76 by $0.04. The business had revenue of $23.99 billion for the quarter, compared to analyst estimates of $23.73 billion. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.42 EPS. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Wall Street Analyst Weigh In

Several brokerages have commented on JNJ. Argus set a $210.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Wells Fargo & Company lifted their target price on Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Raymond James Financial increased their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Wolfe Research boosted their price target on Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Finally, The Goldman Sachs Group upped their price objective on Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Four equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $213.33.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.